Orexo AB stock analysis
Orexo AB (0H19) Share Price & Analysis
0H19 Stock Chart & Stats
- Day’s Range
- SEK 1.03 - SEK 1.03
- 52-Week Range
- SEK 1.03 - SEK 22.23
- Previous Close
- SEK 1.03
- Volume
- N/A
- Average Volume (3M)
- 6,738
- Market Cap
- SEK 308.06M
- Enterprise Value
- SEK 337.34M
- Total Cash (Recent Filing)
- SEK 152.60M
- Total Debt (Recent Filing)
- SEK 6.60M
- Price to Earnings (P/E)
- ―
- Beta
- -0.21
- Next Earnings
- Feb 04, 2027 (Est.)
- EPS Estimate
- -1.19
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage
Low reported debt relative to equity reduces near-term solvency pressure and gives Orexo more flexibility than a highly leveraged structure. This supports continued investment in development programs, although preserving that flexibility depends on improving profitability and controlling ongoing losses.
Cost Restructuring
Implemented staff and facility reductions, lower development spending, and partner cost sharing could structurally reduce the company’s cash needs. If executed, the program may extend runway and improve operating leverage, giving Orexo more time to commercialize its pipeline.
Platform And Pipeline Progress
A platform-focused strategy can diversify Orexo beyond mature products by supporting multiple pharmaceutical and delivery programs. Progress in AmorphOX partnerships may create future milestone, royalty, or commercialization opportunities and strengthen the company’s strategic relevance.
Bears Say
Severe Revenue And Profit Contraction
The sharp revenue contraction and very large net loss indicate that the current business base is not covering the company’s cost structure. Persistently weak operating economics could erode equity, constrain investment capacity, and increase dependence on financing or successful pipeline launches.
Persistent Cash Burn
Negative operating and free cash flow reduce Orexo’s ability to fund development internally and make financial stability dependent on cost reductions, partnering proceeds, or additional capital. If the burn rate persists, financing needs could limit strategic flexibility over the next several quarters.
Maturing Royalty Base
Declining royalties from established products create a structural headwind for recurring revenue while replacement products remain under development. This weakens near-term revenue visibility and increases the importance of regulatory approvals, launches, and partnerships to rebuild the earnings base.
0H19 FAQ
What was Orexo AB’s price range in the past 12 months?
What is Orexo AB’s market cap?
When is Orexo AB’s upcoming earnings report date?
How were Orexo AB’s earnings last quarter?
Is Orexo AB overvalued?
Does Orexo AB pay dividends?
What is Orexo AB’s EPS estimate?
How many shares outstanding does Orexo AB have?
What happened to Orexo AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Orexo AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Orexo AB
Orexo AB (publ), a specialty pharmaceutical company, develops and commercializes pharmaceuticals and digital therapies in the United States, European Union, the United Kingdom, and internationally. Its products include Zubsolv tablets for the treatment of opioid use disorder; Abstral for the treatment of breakthrough pain in cancer patients; and Edluar for the treatment of insomnia. The company is developing OX124 for opioid overdose; OX125 for rescue medication and opioid overdose; OX640 to treat anaphylaxis with powder-based epinephrine; and OX-MPI for the treatment of endometriosis. Its digital therapies include deprexis for the treatment of depression; vorvida for alcohol management; and modia for opioid use disorder. The company has a collaboration agreement with Abera Bioscience AB to develop nasal powder vaccines based on the AmorphOX technology. Orexo AB (publ) was founded in 1994 and is headquartered in Uppsala, Sweden.
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Nikolaj Sorensen
- Employees
- 55
- Website
- www.orexo.com
- Address
- Virdings Allé 22, Uppsala, UP, 11148, SE
Orexo AB (0H19) Earnings & Revenues
0H19 Company Deck
0H19 Earnings Call
Earnings Call SentimentPositive
The call had a cautiously positive operational tone, with meaningful progress on Izipry, OX640, OX390, semaglutide, partnerships, and cost restructuring. However, the company continues to face substantial financial pressures, including low revenue, a SEK 118 million loss from continued operations, negative cash flow, reduced own cash of SEK 62 million, large historical Zubsolv-related obligations, and pending regulatory and partnering milestones. The number and importance of development milestones and the planned rights issue outweighed the challenges, supporting an overall positive sentiment.
View all GB:0H19 earnings summariesTechnical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 1 | 16 |
| Technical Analysis | 4 | 1 | 4 |
| Moving Averages | 0 | 0 | 12 |
Similar Stocks
| Company | Price & Change | Follow |
|---|---|---|
| SE:SOBISwedish Orphan Biovitrum AB | ||
| SE:CAMXCamurus AB | ||
| SE:ALZCURAlzeCure Pharma AB | ||
| SE:IRLAB.AIRLAB Therapeutics AB Class A | ||
| SE:XSPRAYXspray Pharma AB |










